Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy - A randomized controlled study

Nephrology Dialysis Transplantation

Volumn 24, Issue 10, 2009, Pages 3103-3107

  Ferrario, Francesca ^a   Barone, Maria Teresa ^a   Landoni, Giovanni ^b   Genderini, Augusto ^a   Heidemperger, Marco ^a   Trezzi, Matteo ^a   Piccaluga, Emanuela ^a   Danna, Paolo ^a   Scorza, Daniele ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Acute renal failure; Contrast nephropathy; Isosmolar contrast media; N acetylcysteine; Renal replacement therapy

Indexed keywords

ACETYLCYSTEINE; CREATININE; IODIXANOL; PLACEBO; SODIUM CHLORIDE;

AGED; ANGIOCARDIOGRAPHY; ANGIOGRAPHY; ANGIOPLASTY; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTRAST INDUCED NEPHROPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; FLUID THERAPY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION;

ACETYLCYSTEINE; AGED; CONTRAST MEDIA; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; OSMOLAR CONCENTRATION; PROSPECTIVE STUDIES;

EID: 70349482079     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp306     Document Type: Article

References (44)

1. Rihal CS, Textor SC, Grill DE et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259-2264
2. Curhan GC. Prevention of contrast nephropathy. JAMA 2003; 289: 606-608
3. Heyman SN, Rosenberger C, Rosen S. Regional alteration in renal haemodynamics and oxygenation: a role in contrast medium-induced nephropathy. Nephrol Dial Transplant 2005; 20(S1): i6-i11
4. Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int 2005; 68: 14-22
5. Trivedi HS, Moore H, Nasr S et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 2003; 93: C29-C34
6. Solomon R, Werner C, Mann D et al. Effects of saline, mannitol and furosemide on acute to prevent acute decreases in renal function induced by radiocontrast agents. NEJM 1994; 331: 1416-1420
7. Wang YXJ, Jia YF, Chen KM et al. Radioghraphic contrast media-induced nephropathy: experimental observations and the protective effect of calcium channel blockers. Br J Radiol 2001; 74: 1103-1108
8. Wang A, Holcslaw T, Bashore TM et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 2000; 57: 1675-1680
9. Stone GW, McCullough PA, Tumlin JA et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy. A randomised controlled trial. JAMA 2003; 290: 2284-2291
10. Ix JH, McCulloch CE, Chertow GM. Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. Nephrol Dial Transplant 2004; 19: 2747-2753
11. Kurnik BRC, Allgren RL, Genter FC et al. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 1998; 31: 674-680
12. Efrati S, Dishy V, Averbukh M et al. The effect of N-acetylcysteine on renal function, nitric oxide and oxidative stress after angiography. Kidney Int 2003; 64: 2182-2187
13. Tepel M, Van Der Giet M, Schwarzfeld C et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. NEJM 2000; 20: 180-184
14. Vallero A, Cesano G, Pozzato M et al. Nefropatia da contrasto in car-diologia interventistica: assenza di vantaggi con impiego profilattico di N-Acetilcisteina. GIN 2002; 19: 529-533
15. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. JACC 2002; 40: 1383-1388
16. Briguori C, Manganelli F, Scarpato P et al. Acetylcysteine and contrast agent-associated nephrotoxicity. JACC 2002; 40: 298-303
17. Durham JD, Caputo C, Dokko J et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiogra-phy. KI 2002; 62: 2202-2207
18. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (The APART Trial). Am J Cardiol 2002; 89: 356-358
19. Kay J, Chow WH, Chan TM et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention. A randomized controlled trial. JAMA 2003; 289: 553-558
20. Fung JW, Szeto CC, Chan WW et al. Effect of N-Acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. AJKD 2004; 43: 801-808
21. Webb JG, Pate GE, Humphries KH et al. A randomised controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after catheterisation: lack of effect. Am Heart J 2004; 148: 422-429
22. Goldemberg I, Shechter M, Matetzky S et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. Eur Heart J 2004; 25: 212-218
23. BoccalandroF,AmhadM,Smalling RWet al. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv 2003; 58: 336-341
24. Tadros GM, Mouhayar EN, Akinwande AO et al. Prevention of radiocontrast-induced nephropathy with N-acetylcysteine in patients undergoing coronary angiography. J Invas Cardiol 2003; 15: 311-314
25. MacNeill B, Harding SA, Bazari H et al. Prophylaxis of contrast-induced nephropathy in patient undergoing coronary angiography. J Invas Cardiol 2003; 60: 458-461
26. Bagshaw SM, Ghali WA. Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis. BMC Med 2004; 2: 38
27. Biondi-Zoccai GG, Lotrionte M, Abbate A et al. Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study. BMJ 2006; 332: 202-209
28. Zagler A, Azadpour M, Mercado C et al. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J 2006; 151: 140-145
29. Aspelin P, Aubry P, Fransson SG et al. Nephrotoxic effects in high-risk patients undergoing angiography. NEJM 2003; 348: 491-499
30. Dangas G, Iakovou I, Nikolsky E et al. Contrast-induced nephropathy after percutaneous coronaryinterventionsin relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 2005; 95: 13-19
31. Briguori C, Colombo A, Violante A et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephropathy. Europ Heart J 2004; 25: 206-211
32. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002; 39: 930-936
33. Weisbord S. The high cost of acute renal failure following the administration of intravenous contrast media in hospitalised patients. J Am Soc Nephrol 2002; 13: 447
34. Solomon R. Radiocontrast-induced nephropathy. Semin Nephrol 1998; 18: 551-557
35. Katholi RE, Woods WT Jr, Taylor GJ et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis 1998; 32: 64-71
36. Heyman SN, Goldfarb M, Shina A et al. N-acetylcysteine ameliorates renal microcirculation: Studies in rats. Kidney Int 2003; 63: 634-641
37. Efrati S, Dishy V, Averbukh M et al. The effect of N-acetylcysteine on renal function, nitric oxide and oxidative stress after angiography. Kidney Int 2003; 64: 2182-2187
38. Nallamothu BK, Shojania KG, Saint S et al. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am J Med 2004; 117: 938-947
39. Aspelin Aubry P, Fransson SG et al. Nephrotoxic effects in high-risk patients undergoing angiography. NEJM 2003; 348: 491-499
40. McCullough PA, Bertrand ME, Brinker JA et al. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol 2006; 48: 692-1629
41. Liss P, Persson PB, Hansell P et al. Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media. Kidney Int 2006; 70: 1811-1817
42. Oldemeyer JB, Biddle WP, Wurdeman RL et al. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiogra-phy. Am Heart J 2003; 146: 23
43. Toprak O, Cirit M, Yesil M et al. Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease. Nephrol Dial Transplant 2007; 22: 819-826
44. Toprak O. Interactions between serum creatinine, volume status, N-acetylcysteine and contrast-induced nephropathy. Ren Fail 2006; 28: 265-266